NIA: Alzheimer's Biomarker Tests Suited for Research, Not Clinic | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic biomarker-based tests designed to predict individual risk for Alzheimer's disease may be valuable in research projects and potential treatments, but they are not ready to provide valuable information for use in predicting disease risk in the clinic, according to a new set of Alzheimer's diagnostic guidelines issued Tuesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.